全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Hepatic Myelopathy in a Patient with Decompensated Alcoholic Cirrhosis and Portal Colopathy

DOI: 10.1155/2012/735906

Full-Text   Cite this paper   Add to My Lib

Abstract:

Cirrhotic or hepatic myelopathy is a rare neurological complication of chronic liver disease usually seen in adults and presents as a progressive pure motor spastic paraparesis which is usually associated with overt liver failure and a surgical or spontaneous systemic portocaval shunt. We describe the development of progressive spastic paraparesis, in a patient with alcoholic cirrhosis with portal hypertension and portal colopathy who presented with the first episode of hepatic encephalopathy. The patient had not undergone any shunt procedure. 1. Introduction Hepatic myelopathy (HM) is an insidious onset pure motor spastic paraparesis without sensory or bladder or bowel involvement in patients with liver disease in which the neurological dysfunction cannot be attributed to another disorder. A progressive spastic paraparesis in patients with hepatic failure was first described by Leigh and Card [1], followed by a detailed description of HM??by other authors who observed this rare neurological complication of cirrhosis, especially in patients with portosystemic shunts [2–4]. In India, HM was reported for the first time by Pant et al. who described two cases of spastic paraparesis in patients with liver cirrhosis, one with a spontaneous portocaval shunt and the other with a surgical portocaval anastamosis [5]. The typical clinical presentation of this disorder is of a patient with underlying chronic liver disease, developing progressive pure motor spastic paraparesis with minimal or no sensory deficit and without bowel and bladder involvement. Most patients report prior episodes of hepatic encephalopathy, and in many cases, the development of myelopathy follows the creation of surgical shunts [6–8]. Early and accurate diagnosis of??HM??is important because patients with early stages of the disease can recover following liver transplantation [9]. Neuropathological studies show demyelination in the lateral corticospinal tracts, with varying degrees of axonal loss [2]. Motor-evoked potential studies may be suitable for the early diagnosis of??hepatic??myelopathy, even in patients with preclinical stages of the disease [10]. 2. Case Presentation A 45-year-old male farmer, hailing from Uttar Pradesh, north India, presented to us with complaints of difficulty in walking due to stiffness of lower limbs for 2 years, associated with weakness. Initially, the weakness was only present on activities like standing from the squatting position or climbing stairs which over a period of a couple of months progressed to noticing slippage of footwear and dragging of feet

References

[1]  A. D. Leigh and W. I. Card, “Hepato-lenticular degeneration. A case associated with postero-lateral column degeneration,” Journal of Neuropathology & Experimental Neurology, vol. 8, pp. 318–346, 1949.
[2]  L. Zieve, D. F. Mendelson, and M. Goepfert, “Shunt encephalomyelopathy. II. Occurrence of permanent myelopathy,” Annals of Internal Medicine, vol. 53, pp. 53–63, 1960.
[3]  I. A. Brown, Liver-Brain Relationships, Thomas Y Crowell, Springfield, 1957.
[4]  S. M. Gospe Jr., R. D. Caruso, M. S. Clegg et al., “Paraparesis, hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis,” Archives of Disease in Childhood, vol. 83, no. 5, pp. 439–442, 2000.
[5]  S. S. Pant, A. N. Bhargava, M. M. Singh, et al., “Myelopathy in hepatic cirrhosis,” British Medical Journal, vol. 1, pp. 1064–1065, 1963.
[6]  G. Mendoza, J. Marti-Fabregas, J. Kulisevsky, and A. Escartin, “Hepatic myelopathy: a rare complication of portacaval shunt,” European Neurology, vol. 34, no. 4, pp. 209–212, 1994.
[7]  J. Panicker, S. Sinha, A. B. Taly, S. Ravishankar, and G. R. Arunodaya, “Hepatic myelopathy: a rare complication following extrahepatic portal vein occlusion and lienorenal shunt,” Neurology India, vol. 54, no. 3, pp. 298–300, 2006.
[8]  J. V. Campellone, D. Lacomis, M. J. Giuliani, and F. J. Kroboth, “Hepatic myelopathy. Case report with review of the literature,” Clinical Neurology and Neurosurgery, vol. 98, no. 3, pp. 242–246, 1996.
[9]  K. Weissenborn, U. J. F. Tietge, M. Bokemeyer et al., “Liver transplantation improves hepatic myelopathy: evidence by three cases,” Gastroenterology, vol. 124, no. 2, pp. 346–351, 2003.
[10]  R. Nardone, T. Buratti, A. Oliviero, A. Lochmann, and F. Tezzon, “Corticospinal involvement in patients with a portosystemic shunt due to liver cirrhosis: a MEP study,” Journal of Neurology, vol. 253, no. 1, pp. 81–85, 2006.
[11]  L. G. Lefer and F. S. Vogel, “Encephalomyelopathy with hepatic cirrhosis following portosystemic venous shunts,” Archives of Pathology, vol. 93, no. 2, pp. 91–97, 1972.
[12]  M. Demirci, E. Tan, B. Elibol, G. Gedikoglu, and O. Saribas, “Spastic paraparesis associated with portal-systemic venous shunting due to congenital hepatic fibrosis,” Neurology, vol. 42, no. 5, pp. 983–985, 1992.
[13]  K. Mandal and N. Chopra, “Acute transverse myelitis following hepatitis E virus infection,” Indian Pediatrics, vol. 43, no. 4, pp. 365–366, 2006.
[14]  K. Sriram, S. K. Shankar, M. R. Boyd, and V. Ravindranath, “Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration,” Journal of Neuroscience, vol. 18, no. 24, pp. 10287–10296, 1998.
[15]  V. Ravindranath, “Neurolathyrism: mitochondrial dysfunction in excitotoxicity mediated by L-β-oxalyl aminoalanine,” Neurochemistry International, vol. 40, no. 6, pp. 505–509, 2002.
[16]  J. C. Kincaid, “Myelitis and myelopathy,” in Clinical Neurology, R. J. Joynt, Ed., vol. 3, pp. 1–36, JB Lippincott Company, Philadelphia, Pa, USA, 1992.
[17]  C. Counsell and C. Warlow, “Failure of presumed hepatic myelopathy to improve after liver transplantation,” Journal of Neurology Neurosurgery and Psychiatry, vol. 60, no. 5, p. 590, 1996.
[18]  R. Troisi, J. Debruyne, and B. De Hemptinne, “Improvement of hepatic myelopathy after liver transplantation,” The New England Journal of Medicine, vol. 340, no. 2, p. 151, 1999.
[19]  C. Caldwell, N. Werdinger, S. Jakab, et al., “Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature,” Liver Transplantation, vol. 16, no. 7, pp. 818–826, 2010.
[20]  H. S. Malhotra, V. K. Paliwal, M. K. Singh, and A. Agarwal, “Hepatic myelopathy: an unusual complication of advanced hepatic disease,” Annals of Neurosciences, vol. 14, no. 1, 2007.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413